Introduction
============

Opiate addiction is a chronic distressing brain disorder for which there are limited successful treatments that do not rely on the administration of synthetic opiate analogs ([@B60]). One potential non-opioidergic therapeutic target is the endocannabinoid system. A review of the preclinical animal literature suggests that the endocannabinoid system is necessary for the development of opiate dependence and could prove to be useful in the treatment of opiate withdrawal.

Cannabinoids On Opiate Withdrawal
=================================

In animals, as in humans, opioid dependence is produced through chronic opiate exposure, or even, following the single administration of a high dose of an opiate, a state termed acute opiate dependence ([@B18]; [@B25]). Once dependent, withdrawal can be induced either spontaneously through drug abstinence, or precipitated through the administration of an opiate antagonist such as naloxone. In each instance, dependent animals will display numerous somatic and behavioral symptoms that are characteristic of the withdrawal state experienced by human opiate addicts ([@B24]). The ability of different pharmacological manipulations to alter the severity or presence of these symptoms can be used as a measure of their potential in the treatment of opiate detoxification.

Somatic Withdrawal
------------------

In animals, the intensity of somatic withdrawal is quantified by scoring the presence or severity of several physical signs for 10--30 min immediately following precipitated withdrawal, or every 6--9 h for several days following spontaneous withdrawal ([@B33]). To facilitate the quantification of the withdrawal syndrome, [@B14] developed a weighted scale consisting of graded symptoms including percentage of weight loss, number of escape jumps, number of wet dog shakes, number of abdominal constrictions, and checked signs including diarrhea, facial fasciculations/teeth chattering, swallowing, salivation, chromodacryorrhea, ptosis, abnormal posture, erection/ejaculation/genital grooming, and irritability. In assessing the ability of pharmacological cannabinoid manipulations to alleviate the intensity of somatic withdrawal, most studies use a variation of this scale to determine whether individual signs or a global rating of withdrawal has significantly decreased.

A review of the literature reveals that activation of the cannabinoid system acutely prior to withdrawal, or chronic inhibition of the system during the development of dependence, is most effective in reducing withdrawal severity (see **Table [1](#T1){ref-type="table"}** for specific agonists and antagonists and original references). In the majority of cases, acute treatment with a cannabinoid agonist (in particular agonists of the CB~1~ receptor) immediately prior to the induction of withdrawal in highly dependent animals (whether precipitated or spontaneous) is able to attenuate several aspects of the syndrome. Notably, a reduction in the incidence of escape jumps, paw tremors, weight loss, and diarrhea were most commonly reported in rodents (see **Table [1](#T1){ref-type="table"}** for original references). Exceptions to the reductions in withdrawal occurred only when the agonist (Δ^9^THC) was administered chronically during the development of morphine dependence ([@B8]; [@B15]), when rats were made acutely dependent on morphine prior to withdrawal ([@B20]), or when the cannabinoid tested, cannabidiol, was not a CB~1~ receptor agonist ([@B22],[@B23]; [@B7]).

###### 

Effect of different cannabinoid compounds on spontaneous or precipitated somatic and affective opioid withdrawal.

                                            Cannabinoid compound                     Dosing             Effect on withdrawal      Animal             Reference
  ----------- ----------------------------- ---------------------------------------- ------------------ ------------------------- ------------------ ------------------------------------
  Somatic     Precipitated                  **Agonists**                                                                                             
                                            AEA                                      Acute              Reduced                   Mice               [@B64]
                                            2-AG                                     Acute              Reduced                   Mice               [@B71]
                                            Δ^9^ THC                                 Acute              Reduced                   Mice               [@B13]
                                                                                     Acute              Reduced                   Mice               [@B45]
                                                                                     Acute/co-chronic   Reduced/enhanced          Mice               [@B8]
                                                                                     Acute              Reduced                   Mice               [@B29]
                                                                                     Pre-chronic        Reduced                   Mice               [@B63]
                                                                                     Acute              Reduced                   Mice               [@B64]
                                                                                     Acute              Reduced                   Rats               [@B7]^†^
                                                                                     Acute              Reduced                   Rats               [@B74]^†^
                                                                                     Acute              Reduced                   Mice               [@B5],[@B6]
                                                                                     Acute/co-chronic   Reduced                   Guinea Pigs/rats   [@B12]
                                                                                     Acute              Reduced/enhanced          Rats               [@B19],[@B20],[@B21],[@B22],[@B23]
                                                                                     *Acute*            *No effect*               *Rats*             *[@B20]*
                                            Δ^8^ THC                                 Acute              Reduced                   Mice               [@B71]
                                                                                     Acute              Reduced                   Mice               [@B5]
                                            11 hydroxy -- Δ^8^ THC                   Acute              Reduced                   Mice               [@B5]
                                            CBD (non-CB~1~)                          Acute              No effect                 Rats               [@B7]^†^
                                                                                     Acute              Reduced                   Mice               [@B5]
                                                                                     Acute              No effect                 Rats               [@B22],[@B23]
                                            CBN                                      Acute              Reduced                   Rats               [@B7]^†^
                                                                                     Acute              Reduced                   Mice               [@B5]
                                                                                     Acute              No effect                 Rats               [@B22]
                                            HU-210                                   Acute              Reduced                   Mice               [@B71]
                                            O-1602 (GPR55 agonist)                   Co-chronic         Reduced                   Mice               [@B1]
                                            **AEA transport inhibitor**                                                                              
                                            AM404                                    Acute              No effect                 Mice               [@B10]
                                            **FAAH inhibitors**                                                                                      
                                            PF-3845                                  Acute              No effect                 Mice               [@B13]
                                                                                     Acute              Reduced                   Mice               [@B45]
                                            URB-597                                  Acute              Reduced                   Rats               [@B53]
                                            **FAAH KO**                                                 Reduced                   Mice               [@B45]
                                            **MAGL inhibitor**                                                                                       [@B13]
                                            JZL-184                                  Acute              Reduced                   Mice               [@B45]
                                            **Dual FAAH/MAGL**                                                                                       
                                            **Inhibitors**                                                                                           
                                            SA-57                                    Acute              Reduced                   Mice               [@B13]
                                            JZL-184 + PF-3845                        Acute              Reduced                   Mice               [@B44]
                                            **CB~1~ KO**                                                Reduced                   Mice               [@B31]
                                                                                                        Reduced                   Mice               [@B29]
                                                                                                        Reduced                   Mice               [@B28]
                                            **CB~1~ antagonists/inverse agonists**                                                                   
                                            Rimonabant                               Acute/co-chronic   Reduced aspects/reduced   Rats               [@B61]
                                                                                     Acute/co-chronic   No effect/reduced         Mice               [@B37]
                                                                                     Co-chronic         Reduced/enhanced          Rats               [@B47]
                                                                                     Acute              No effect                 Rats               [@B41]
                                            AM251                                    Acute/co-chronic   No effect/reduced         Rats               [@B61]
              Spontaneous                   **Agonists**                                                                                             
                                            Δ^9^ THC                                 Co-chronic         No effect                 Monkeys            [@B15]
                                                                                     Acute              Reduced                   Dogs               [@B16]
                                            Nabilone                                 Acute              Reduced                   Dogs               [@B16]
                                            Nantradol                                Acute              Reduced                   Dogs               [@B16]
                                                                                     Acute              Reduced                   Monkeys            [@B73]
                                            Levonantradol                            Acute              Reduced                   Monkeys            [@B73]
                                            **AEA transport inhibitor**                                                                              
                                            AM404                                    Acute              Reduced                   Mice               [@B10]
                                            **MAGL inhibitor**                                                                                       
                                            JZL-184                                  Acute              Reduced                   Mice               [@B45]
                                            **Dual FAAH/MAGL inhibitors**                                                                            
                                            SA-57                                    Acute              Reduced                   Mice               [@B44]
                                            JZL-184 + PF-3845                        Acute              Reduced                   Mice               [@B44]
                                            **CB~1~ antagonist/inverse agonist**                                                                     
                                            Rimonabant                               Acute              Failed to precipitate     Mice               [@B29]
                                                                                     Acute              Precipitated              Rats               [@B41]
                                                                                                                                                     
  Affective   CPA paradigm                  **Agonists**                                                                                             
                                                                                                                                                     
                                                                                                                                                     
                                            Δ^9^ THC                                 Acute              No effect                 Mice               [@B13]
                                            **FAAH inhibitors**                                                                                      
                                            PF-3845                                  Acute              No effect                 Mice               [@B13]
                                                                                     *Acute*            *No effect*               *Rats*             *[@B68]*
                                            URB-597                                  *Acute*            *No effect*               *Rats*             *[@B68]*
                                            **MAGL inhibitors**                                                                                      
                                            JZL-184                                  Acute              No effect                 Mice               [@B13]
                                            MJN110                                   *Acute*            *Reduced*                 *Rats*             *[@B68], [@B67]*
                                            **Dual FAAH/MAGL inhibitor**                                                                             
                                            SA-57                                    Acute              No effect                 Mice               [@B13]
                                            **CB~1~ KO**                                                No effect                 Mice               [@B35]
                                                                                                        Reduced                   Mice               [@B28]
                                            **CB~1~ antagonists/inverse agonists**                                                                   
                                            Rimonabant                               Acute              Precipitated              Rats               [@B40]^‡^
                                            AM251                                    *Acute*            *Reduced*                 *Rats*             *[@B68], [@B67]*
                                            **CB~1~ neutral antagonist**                                                                             
                                            AM4113                                   *Acute*            *Reduced*                 *Rats*             *[@B68]*
                                            AM6527                                   *Acute*            *Reduced*                 *Rats*             *[@B68]*
              Operant responding for food   **CB~1~ antagonist/inverse agonist**                                                                     
                                                                                                                                                     
                                                                                                                                                     
                                            Rimonabant                               Acute              Precipitated              Rats               [@B40]^‡^
                                                                                                                                                     

Dosing reflects whether compounds were given acutely prior to withdrawal, pre-chronic (chronically prior to morphine administration), or co-chronic (concurrently with morphine during the development of dependence).

Italicized rows

indicate experiments tested on acutely dependent animals.

†

Quasi morphine withdrawal,

‡

spontaneous withdrawal.

Somewhat contradictory, CB~1~ receptor knock-out (KO) mice show reduced somatic opioid withdrawal and cannabinoid antagonists (rimonabant and AM251) interfere with somatic opioid withdrawal (see **Table [1](#T1){ref-type="table"}**). However, contrary to the cannabinoid agonists, antagonists were most effective in reducing withdrawal when delivered chronically (not acutely) during the development of opiate dependence. Indeed, when given chronically prior to precipitating withdrawal with naloxone, rimonabant and AM251 reliably reduced withdrawal severity ([@B47]; [@B37]; [@B61]). In contrast, when delivered acutely, antagonists were either without effect ([@B41]; [@B37]; [@B61]), or their ability to attenuate withdrawal was markedly reduced ([@B61]). In a case of spontaneous withdrawal ([@B41]), acute rimonabant treatment was even found to precipitate withdrawal in morphine-dependent rats, however, this finding was not replicated when tested in mice ([@B29]). Ultimately, these findings, along with the results from the agonist studies, suggest that the endocannabinoid system plays an important role in the development of somatic opioid dependence and activation of the system during withdrawal, or chronic blockade during opioid dependence, can mitigate some of its adverse effects.

Unfortunately, CB~1~ receptor (CB~1~R) agonists and inverse agonists/antagonists are known to produce undesirable side effects (e.g., psychoactivity, depression) which limit their therapeutic potential ([@B39]). Therefore, it is fortunate that non-psychoactive treatments (including Fatty Acid Amide Hydrolase \[FAAH\] and monoacylglycerol lipase \[MAGL\] inhibitors) which act to enhance endogenous cannabinoid tone have also been effective in alleviating somatic withdrawal (see **Table [1](#T1){ref-type="table"}** for specific agents and original references). While inhibition of the MAGL enzyme (which elevates endogenous 2-arachidonoyl glycerol \[2-AG\]) produced the most robust effects ([@B45]; [@B13]), inhibitors or KO mice of the catabolic FAAH enzyme (which elevates endogenous anandamide \[AEA\]) reduced a subset of withdrawal symptoms in most cases ([@B45]; [@B53]), whereas the AEA transport inhibitor, AM404, was without effect ([@B10]). However, unlike FAAH inhibitors, MAGL inhibitors have been found to produce cannabimimetic side effects (e.g., hypomotility, hyperreflexia; [@B30]) and can lead to the development of dependence and tolerance with repeated administration ([@B51]). In light of this, [@B44] and [@B13] tested the combinations of low doses of FAAH and MAGL inhibitors, or dual FAAH/MAGL inhibitors, for their effectiveness in reducing withdrawal maximally without additional side effects. Indeed, this combination of catabolic enzyme inhibitors proved to be highly effective in reducing withdrawal (including jumping, paw flutters, head shakes, diarrhea, and weight loss) but was absent of adverse effects. Consequently, when considering pharmacological interventions that may aid in the treatment of somatic aspects of opiate withdrawal, dual FAAH/MAGL inhibition (at low doses) is most promising.

Affective Withdrawal
--------------------

In animals, affective opioid withdrawal can be measured using a number of motivational paradigms including the conditioned place aversion (CPA), intracranial self-stimulation, and operant responding for food ([@B33]). In evaluating the role of the endocannabinoid system in affective opioid withdrawal, the CPA paradigm has been most commonly employed. This paradigm typically involves pairing naloxone-precipitated morphine withdrawal (in acutely or chronically dependent animals) with a specific environmental context, such that, upon re-exposure to this context in a drug-free state, animals will preferentially avoid the withdrawal paired context versus a context that was previously paired with a placebo saline injection ([@B48]). This avoidance of the withdrawal context is used as a measure of the intensity of the aversive affect experienced during opioid withdrawal, and can be used to assess the potential of pharmacological treatments to reduce affective withdrawal. Indeed, pharmacological treatments that are currently used in the treatment of opioid withdrawal (e.g., buprenorphine) are effective in reducing the establishment of avoidance behavior in this paradigm ([@B58]). Also employed is the operant responding for food paradigm ([@B40]). In this paradigm, a pharmacological treatment is deemed effective in reducing affective withdrawal if it is able to suppress a withdrawal-induced reduction in operant responding for food ([@B33]).

A review of the literature reveals a more complicated role for the endocannabinoid system in its ability to alleviate affective opioid withdrawal than was observed for somatic withdrawal (see **Table [1](#T1){ref-type="table"}**); granted the studies conducted thus far are fairly limited. Indeed, as with somatic withdrawal, both activation and inhibition of the cannabinoid system has been found effective in reducing affective opioid withdrawal, but with greater inconsistencies. Contrary to somatic withdrawal, the cannabinoid agonist, Δ^9^THC, and the FAAH enzyme inhibitors, PF3845 and URB-597, tested were unable to modify the establishment of a naloxone-precipitated CPA ([@B68]; [@B13]). However, while activation of the cannabinoid system via exogenous cannabinoid administration or endogenous elevation of AEA proved to have little efficacy, inhibition of MAGL activity and concomitant elevation of 2-AG showed mixed ([@B68], [@B67]; [@B13]) but more promising results. Given that these discrepant findings were obtained by different laboratories using different procedures, compounds (JZL-184 vs. MJN110), and species (mice vs. rats), more research into the potential of MAGL inhibition in reducing affective opioid withdrawal will be required in order to elucidate its role. Furthermore, while the only dual FAAH/MAGL inhibitor (SA-57) investigated was unable to modify a naloxone-precipitated CPA ([@B13]), additional research into the ability of such compounds to reduce affective withdrawal should continue owing to their effectiveness in reducing somatic withdrawal with minor adverse effects (noted in previous section).

Although the deleterious reputation of cannabinoid antagonists/inverse agonists may limit their therapeutic potential ([@B4]), blockade of the endocannabinoid system may be effective for reducing affective opioid withdrawal. Indeed, acute CB~1~R antagonism (with both AM251, and the neutral CB~1~ antagonists, AM4113, and AM6527) was effective in preventing the establishment of a naloxone-precipitated CPA ([@B68], [@B67]). This is in contrast to the ability of acute CB~1~ antagonism to reliably reduce somatic withdrawal, but could be attributed to the fact that the CPA paradigm may provide a more sensitive measure of opioid withdrawal ([@B3]). Of special consideration is that both antagonists (which have been found to possess inverse agonist activity) and neutral antagonists (void of intrinsic activity; [@B56]) were effective in preventing the establishment of the CPA. This is particularly important since these 'neutral' antagonists have also been found to lack the adverse qualities attributed to typical cannabinoid antagonists ([@B4]). While the only evaluations of chronic inhibition of the endocannabinoid system (CB~1~ KO mice) yielded mixed results ([@B28]; [@B35]), chronic antagonism of the endocannabinoid system during the development of dependence using 'neutral' antagonists should be investigated given that acute treatments have been reported to precipitate both spontaneous affective and somatic withdrawal ([@B41], [@B40]).

Neurobiological Correlates and Potential Mechanisms of Interaction
==================================================================

Although the exact mechanisms through which the endocan nabinoid system is able to modulate opioid withdrawal remain to be elucidated, several theories have been proposed. Briefly, it has been hypothesized that cannabinoid and opioids interact through (1) reciprocal endogenous neurotransmitter/peptide release, (2) common signal-transduction pathways, and (3) receptor heterodimerization (see [@B42]; [@B50], for a review). An overview of these mechanisms in the brain regions most attributed to somatic and affective withdrawal is discussed.

Somatic Withdrawal
------------------

The neuroanatomical substrates most sensitive to the appearance of somatic opioid withdrawal include the periaqueductal gray (PAG) and locus coeruleus (LC; see [@B33], for a review). Indeed, microinjection of methylnaloxonium, a hydrophilic opiate antagonist, into these regions was most sensitive in eliciting the opiate withdrawal syndrome, with active symptoms such as jumping being particularly prominent ([@B32]). In revisiting the withdrawal symptoms most commonly attenuated by cannabinoid modulation (e.g., jumping and paw tremors), it becomes apparent that these neuroanatomical substrates may represent regions through which cannabinoids interact with the opioid system to attenuate somatic withdrawal.

Much evidence indicates the PAG as a locus for cannabinoid--opioid interactions. Indeed, anatomical immunolabeling has co-localized the CB~1~R and μ-opioid receptor (MOR) within this region. Furthermore, 8% of immunoreactive MOR PAG neurons received immunoreactive CB~1~R appositions, indicating a role for presynaptic cannabinoid modulation ([@B70]). In addition, sub-chronic CB~1~R agonist treatment with THC or AM356 was reported to increase proenkephalin mRNA levels in the PAG ([@B34]). A reciprocal effect following repeated morphine treatment is also suggested given the ability of the CB~1~R antagonist AM251 to increase the frequency of spontaneous miniature inhibitory postsynaptic currents (IPSCs) in morphine, but not saline treated animals, suggesting an elevation of endocannabinoid tone ([@B69]). Chronic (up to 7 days) CB~1~R agonist treatment has also been reported to up-regulate MOR density ([@B66]), with tolerance developing with prolonged (14 day) treatment ([@B9]). Finally, chronic THC pre-opiate exposure or acute rimonabant treatment has been found to induce or attenuate Fos immunoreactivity in the PAG from acute heroin or morphine administration, respectively ([@B55], [@B54]).

While the investigation of cannabinoid--opioid interaction in the LC is less extensive than in the PAG, a recent anatomical study confirmed the co-existence of MOR and CB~1~R immunoreactivity in somatodendritic compartments of catecholaminergic neurons. Additionally, as in the PAG, immunoreactive CB~1~R axon terminals formed synaptic contacts with MOR dendrites ([@B49]). Ultimately, these findings suggest a role for cannabinoid--opioid interactions in the PAG and LC via common signal transduction mechanisms, or potential receptor heterodimerization given their close proximity and reports of this occurrence ([@B52]). Additionally, as discussed above, interactions in endogenous neurotransmitter release are also evident in the PAG. These mechanisms of interaction correspond to the general ability of CB~1~R agonism or chronic CB~1~R antagonism to reduce symptoms of somatic opioid withdrawal.

Affective Withdrawal
--------------------

The brain structures most sensitive to the motivating or affective component of opioid withdrawal include the nucleus accumbens (NAc) and the amygdala (see [@B33], for a review). Indeed, microinjection of hydrophilic opiate antagonists into these regions was most sensitive in producing the establishment of a CPA ([@B59]), and suppressing operant responding in morphine dependent rats ([@B26]). An evaluation of cannabinoid--opioid interactions within these regions also reveals these sites to be crucial in the ability of the cannabinoid system to modulate affective opioid withdrawal.

There is substantial research supporting cannabinoid--opioid interactions within the NAc. As in the PAG and LC, immunolabeling has revealed evidence for CB~1~R and MOR localization on the same neurons in the NAc shell and core, as well as expression on synaptically linked neurons ([@B43]). Furthermore, CB~1~R and MOR allosterically interact in this region causing non-additive and synergistic effects on glutamate and GABA release, respectively. These effects were reversed by their respective antagonists, but antagonist co-administration blocked these antagonistic effects, suggesting the potential for G-protein coupled heterodimeric receptor complexes ([@B52]). Consistent with these findings, reports also suggest CB~1~R and MOR synergy on cAMP/PKA signaling that is mediated through βγ dimers ([@B72]). Chronic opioid and cannabinoid administration has also been found to alter cannabinoid and opioid stimulated G-protein receptor coupling, respectively; though while cannabinoids enhance MOR binding ([@B66]), opioids have produced more mixed effects on CB~1~R binding ([@B65], [@B66]; [@B11]). Reports of changes in receptor densities have also been noted, with chronic opioid administration increasing CB~1~R density ([@B17]), mRNA and protein levels ([@B46]), and cannabinoid agonist treatment increasing MOR density ([@B9]; [@B11]; [@B38]). However, while cannabinoid agonists seem to consistently increase MOR density, the effects of CB~1~R gene deletion have been less consistent in reducing expressivity ([@B62]; [@B27]). Cannabinoid--opioid interactions on neuronal activation and dopamine release have also been reported in the NAc. Indeed, cannabinoid agonists increase while antagonists decrease Fos expression induced by acute morphine ([@B55], [@B54]), and CB~1~R KO mice report decreased morphine-induced dopamine release ([@B36]). Finally, cross-talk on endogenous neurotransmitter and peptide release has also been described, with increased AEA and decreased 2-AG content following chronic opioid administration, and increased Met-enkephalin immunoreactivity ([@B63]), proenkephalin mRNA ([@B34]), and β-endorphin levels ([@B57]) following acute or chronic cannabinoid (THC or CP-55,940) administration. These findings are consistent with the ability of cannabinoid agonists to decrease affective opioid withdrawal and provide evidence for interactions within the NAc at the neurotransmitter, receptor and signal transduction level.

A second region of interest attributed to mediating affective opioid withdrawal is the amygdala. Although there is less research investigating cannabinoid--opioid interactions within this region in comparison to the NAc, effects on receptor density and functionality have been noted. Specifically, acute and repeated cannabinoid agonist (THC or WIN 55,212-2) administration produced increases in MOR density and G-protein receptor coupling in the amygdala ([@B9]; [@B11]). Similar findings were also reported on the effects of chronic opioid administration on CB~1~R density and receptor coupling when considering the amygdala as a whole ([@B11]), however, decreases in CB~1~R density have been described when analyzing the basolateral amygdala (BLA) individually ([@B17]). In addition to receptor interactions, alterations in Fos immunoreactivity (Fos IR; a marker of neuronal activation) have also been noted. Indeed, acute treatment of the cannabinoid antagonist, rimonabant, attenuated acute morphine-induced Fos immunoreactivity in the amygdala as a whole ([@B55]), while investigations of the central nucleus of the amygdala (CeA) specifically revealed decreases in acute heroin-induced Fos IR following chronic THC pre-treatment ([@B54]), and additive effects on naloxone-induced Fos IR following acute THC exposure ([@B2]). Although the above studies do not make any direct comparisons between the BLA and CeA on cannabinoid--opioid interactions, a recent experiment suggests a functional double dissociation between these regions in the ability of the cannabinoid system to modulate affective opioid withdrawal. Indeed, cannabinoid agonism (via inhibition of MAGL activity with MJN110) within the BLA, while cannabinoid antagonism (AM251) within the CeA, is able to interfere with the establishment of a naloxone-precipitated CPA in acutely morphine dependent rats ([@B67]). Though the mechanisms mediating the dissociation between these regions were not investigated, this finding suggests potential differences in cannabinoid--opioid modulation within different sub-regions of the amygdala.

Conclusion
==========

A review of the literature reveals that acute pharmacological activation or chronic inhibition of the cannabinoid system may interfere with opioid withdrawal. In particular, dual FAAH/MAGL enzyme inhibitors or neutral CB~1~R antagonists are most promising, though further investigations are necessary. In the central nervous system, cannabinoid--opioid interactions are abundant and present within neuroanatomical regions important in mediating opioid withdrawal including the amygdala, the NAc, the PAG, and the LC. However, while interactions have been described, more research on the mechanisms through which endocannabinoid modulation is able to attenuate opioid withdrawal will be required in order to gain a more cohesive understanding of its therapeutic potential.

Author Contributions
====================

KW wrote the article; LP edited the article.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This research was funded by NSERC Grant \#92057 to LP and Scholarship to KW.

[^1]: Edited by: *Allyn C. Howlett, Wake Forest School of Medicine, USA*

[^2]: Reviewed by: *Avital Schurr, University of Louisville, USA; Joseph F. Cheer, University of Maryland School of Medicine, USA*

[^3]: This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
